---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-039392"
form_type: "8-K/A"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:21:22.659880+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Esperion amends Q2 earnings; reports $82.4M revenue, first operating income of $7.1M

## Summary
- Net loss narrowed to $12.7M from $61.9M in Q2 2024; EPS loss $0.06 vs $0.33.
- U.S. net product revenue rose 42% Y/Y to $40.3M; total revenue grew 12% to $82.4M.
- Achieved $7.1M operating income, first quarter of positive operating income from ongoing ops.
- Reached ANDA settlements blocking generic bempedoic acid until 2040.
- Cash $86.1M at June 30; expects sustainable profitability starting Q1 2026.

## SEC filing metadata
- accession: 0001628280-25-039392
- form_type: 8-K/A
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025039392/0001628280-25-039392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025039392/espr-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-039392
- JSON: https://secwatch.observer/filing/0001628280-25-039392.json
- Plain text: https://secwatch.observer/filing/0001628280-25-039392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.